Bionoid Pharma Inc.
BINP
$0.08
$0.000.00%
OTC PK
| 03/31/2012 | 03/31/2011 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -91.54% | 48.19% | |||
| Gross Profit | 91.54% | -48.19% | |||
| SG&A Expenses | -89.16% | 1,275.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -89.64% | 1,074.96% | |||
| Operating Income | 89.64% | -1,074.96% | |||
| Income Before Tax | 89.65% | -1,057.28% | |||
| Income Tax Expenses | -- | 155.56% | |||
| Earnings from Continuing Operations | 89.65% | -1,055.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 89.65% | -1,055.39% | |||
| EBIT | 89.64% | -1,074.96% | |||
| EBITDA | 89.76% | -1,095.80% | |||
| EPS Basic | 92.00% | -733.43% | |||
| Normalized Basic EPS | 92.00% | -734.65% | |||
| EPS Diluted | 92.00% | -733.43% | |||
| Normalized Diluted EPS | 92.00% | -734.65% | |||
| Average Basic Shares Outstanding | 29.73% | 38.32% | |||
| Average Diluted Shares Outstanding | 29.73% | 38.32% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||